External speakers

Fast-track notification of cancer to the Victorian Cancer Registry: Using E-Path to provide timely cancer statistics | Professor Sue Evans

Transmitting pathology data in near real-time from pathology laboratories across Victoria, and how artificial intelligence is being used to extract core information from these reports, to enhance the dataset captured by the Victorian Cancer Registry (VCR).

Checkpoints of the TNF signalling pathway: Implications in cancer and inflammation | Dr Najoua Lalaoui

TNF is a pleiotropic cytokine with key roles in inflammation. The TNF signalling is tightly controlled at multiple levels by diverse checkpoints. Removal of these checkpoints unleashes the cytotoxic potential of TNF than can be used for cancer therapy but also drive inflammatory diseases.

Implementing whole genome sequencing in the breast cancer clinic | Dr Amy McCart Reed

Q-IMPROvE is the Qld-based study to investigate the benefit of implementing whole genome sequencing into the management of breast cancer patients.

Unplanned ED presentations by cancer patients receiving anti-cancer therapy | Polly Dufton

The reasons that cancer patients who are receiving systemic anti-cancer therapy make unplanned ED presentations are more complex than you might think.

CD16/complement-expressing macrophages are critical to immunotherapy response in melanoma | Dr James Wilmott

CD16+/C1qa expressing macrophages are a critical component of immune responses to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combination immunotherapies in melanoma patients.

The compelling journey of colorectal cancer prevention by aspirin | Professor Finlay Macrae

From case-control studies to the 20 year follow up of the CaPP2 RCT.

Unique psychological challenges in haematological cancer during the pandemic | Dr Nienke Zomerdijk

National collaborative study to identify the psychological impacts of the COVID-19 pandemic on haematological cancer patients and correlated factors to inform potential appropriate interventions

The ROSA project: options for risk-based breast cancer screening in Australia | Dr Carolyn Nickson

The Roadmap for Optimising Screening in Australia (ROSA) project is actively exploring options for more risk-based approaches to the early detection of breast cancer in asymptomatic women.

Immune surveillance of growth factors in anti-tumour immunity | Dr Alexander Barrow

The Barrow lab is actively investigating how tumour cell-derived growth factors activate anti-tumour immunity focusing on natural killer cells and innate lymphoid cells.

Mass cytometry (CyTOF) technology in cancer drug research | Dr Charis Teh

Mass cytometry (CyTOF) technology captures the cellular gymnastics of survival and killer proteins in blood cancers after drug treatment.

Central venous access devices and cancer care: What we know but don’t implement | Kerrie Curtis

Identifying practice gaps in the management of Central Venous Access Devices in cancer contexts. A multi-site knowledge translation study.

Understanding the functional consequences of every single mutation in Your Favourite Gene

This talk describes Multiplexed Assays of Variant Effect (MAVEs), a family of experimental techniques that allow researchers to measure all possible variants of a gene or other functional element at once, with a focus on enabling MAVE data sharing and clinical applications.

Making Curative Treatment Decisions in Breast Cancer: How Precise Need We Be?

This talk discusses how clinicians make recommendations with patients, predominantly focusing on systemic therapies such as which endocrine therapy to use, how long to use it, and deciding when a patient needs chemotherapy.

The power of molecular imaging techniques in preclinical cancer research

In this seminar Dr Burvenich (NIF fellow, National Imaging Facility) will illustrate the capability of the preclinical molecular imaging modalities available at the ARCF Centre for Translational Cancer Therapeutics and Imaging of the Olivia Newton-John Cancer Research Institute.

Heritable DNA methylation marks associated with familial breast and prostate cancer

Using a CRISPR based system to edit DNA methylation this study screened for methylation that induce a breast cancer phenotype.

Changing the therapeutic paradigm of Gastrointestinal Cancer with precision medicine | Professor Alex Boussioutas

Using precision medicine to shift the therapeutic paradigm of gastrointestinal cancer towards early detection, targeted therapy and prevention.

Suppressing tumour development - the coordinated response of p53 target genes

p53 activates many genes and pathways, thus understanding which are the most important for its tumour suppression function has been a challenge. Our data support the notion that multiple p53-regulated processes must fail for tumours to develop, with coordination of DNA damage repair bring highly critical, earning its title as the ‘guardian of the genome’.

Breast cancer susceptibility genomics: current status, clinical utility and future perspectives

In this seminar, Tú will present the current status, clinical utility and future perspectives of genomic testing for breast cancer susceptibility.

Old and new pre-clinical tools to investigate mechanisms of drug resistance in ovarian and other rare gynaecological cancers

In this seminar, Professor Clare Scott discusses streamlining ovarian and other rare gynaecological cancer research through the national WEHI-Stafford Fox Rare Cancer Program.